This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Satsuma Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Satsuma Pharmaceuticals' CEO is John Kollins, appointed in Jul 2016, he has a tenure of 6.92 years. His total yearly compensation is $1.91M , comprised of 27.8% salary and 72.2% bonuses, including company stock and options. He directly owns 0.94% of the company’s shares, worth €317.23K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.
Informazioni chiave
John Kollins
Amministratore delegato
US$1.9m
Compenso totale
| Percentuale dello stipendio del CEO | 27.8% |
| Mandato del CEO | 6.9yrs |
| Proprietà del CEO | 0.9% |
| Durata media del management | 5.9yrs |
| Durata media del Consiglio di amministrazione | 5.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$2m | US$530k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$830k | US$500k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$456k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$391k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$20m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$568k | US$362k | -US$7m |
Compensazione vs Mercato: John's total compensation ($USD1.91M) is above average for companies of similar size in the German market ($USD407.72K).
Compensazione vs guadagni: John's compensation has increased whilst the company is unprofitable.
AMMINISTRATORE DELEGATO
John Kollins (60 yo)
6.9yrs
Mandato
US$1,909,812
Compensazione
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
| Chief Financial Officer | 4.4yrs | US$936.85k | 0.042% € 14.2k | |
| VP & Head of Operations | 6.4yrs | Nessun dato | Nessun dato | |
| Senior VP & Head of Chemistry | 5.9yrs | Nessun dato | Nessun dato | |
| VP & Head of Regulatory Affairs | 5.1yrs | Nessun dato | Nessun dato |
5.9yrs
Durata media
58yo
Età media
Gestione esperta: 1LV's management team is seasoned and experienced (5.9 years average tenure).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% € 317.2k | |
| Independent Director | 2.9yrs | US$132.08k | 0% € 0 | |
| Independent Director | 5.8yrs | US$131.58k | 0% € 0 | |
| Independent Chairman of the Board | 6.5yrs | US$160.08k | 0% € 0 | |
| Independent Director | 6.5yrs | US$120.58k | 0% € 0 | |
| Independent Director | 1.7yrs | US$124.58k | 0% € 0 | |
| Independent Director | 7yrs | US$124.08k | 0% € 0 | |
| Independent Director | 4.1yrs | US$132.08k | 0% € 0 | |
| Independent Director | 5.7yrs | US$126.08k | 0% € 0 |
5.8yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: 1LV's board of directors are considered experienced (5.8 years average tenure).